Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Biomarkers in Breast Cancer and the Implications of Their Discordance

Biomarkers in Breast Cancer and the Implications of Their Discordance The analysis of biomarkers in breast cancer has made a large impact in treatment decisions and determining prognosis. Information gained from the phenotypic and molecular profile helps both in prognostic stratification as well as treatment selection. With the advent of newer more efficacious chemotherapeutic and biological agents in the management of metastatic breast cancer, most women with this disease are exposed to multiple lines of therapy. Discordance in the receptor status between the primary and metastatic sites is frequently encountered and may play an important role in deciding subsequent therapy. In this review, we look at the role of current biomarkers in the management of breast cancer, which are promising and the therapeutic and prognostic implications of their discordance during the natural course of disease progression. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Breast Cancer Reports Springer Journals

Biomarkers in Breast Cancer and the Implications of Their Discordance

Loading next page...
 
/lp/springer-journals/biomarkers-in-breast-cancer-and-the-implications-of-their-discordance-V4NoTOBYBt

References (78)

Publisher
Springer Journals
Copyright
Copyright © 2013 by Springer Science+Business Media New York
Subject
Medicine & Public Health; Oncology; Internal Medicine; Surgical Oncology
ISSN
1943-4588
eISSN
1943-4596
DOI
10.1007/s12609-013-0126-8
Publisher site
See Article on Publisher Site

Abstract

The analysis of biomarkers in breast cancer has made a large impact in treatment decisions and determining prognosis. Information gained from the phenotypic and molecular profile helps both in prognostic stratification as well as treatment selection. With the advent of newer more efficacious chemotherapeutic and biological agents in the management of metastatic breast cancer, most women with this disease are exposed to multiple lines of therapy. Discordance in the receptor status between the primary and metastatic sites is frequently encountered and may play an important role in deciding subsequent therapy. In this review, we look at the role of current biomarkers in the management of breast cancer, which are promising and the therapeutic and prognostic implications of their discordance during the natural course of disease progression.

Journal

Current Breast Cancer ReportsSpringer Journals

Published: Oct 19, 2013

There are no references for this article.